SHEMINA RANSOM: Open Payments
NPI 1518457928 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$509 in 22 payments from 13 companies in 2025. Trend: 2023 $261 · 2024 $666 · 2025 $509
Food & beverage: $509
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $96 |
| Abbott Laboratories | 5 | $95 |
| Dexcom, Inc. | 2 | $50 |
| RECORDATI_RARE_DISEASES_INC. | 2 | $47 |
| Amgen Inc. | 2 | $38 |
| Insulet Corporation | 1 | $34 |
| Rhythm Pharmaceuticals, Inc. | 1 | $30 |
| Tandem Diabetes Care, Inc. | 1 | $28 |
| Chiesi USA, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
Products named: Ozempic, FREESTYLE LIBRE 3, Dexcom G6 Transmitter, ISTURISA, Omnipod, IMCIVREE, t:slim X2 Insulin Pump with Control-IQ, EVENITY.
Industry payments across MS — which companies pay providers there.
